Table 1 Baseline clinical data
Clinical data | Case group n = 50 | Control group n = 100 | Oxford classification | Case group Cases (%) | Control group Cases (%) |
|---|---|---|---|---|---|
At time of biopsy | Mesangial hypercellularity ** | ||||
Gender (M/F) | 35/15 | 56/44 | M0 | 11 (22.0%) | 72 (72.0%) |
Age (y) | 35.8 ± 9.9 | 35.4 ± 10.1 | M1 | 39 (78.0%) | 28 (28.0%) |
eGFR | 57.3 ± 27.6** | 95.7 ± 32.7 | Endocapillary hypercellularity | ||
sCr (mg/dl) | 1.4 (0.8–4.3)** | 0.9 (0.5–2.1) | E0 | 14 (28.0%) | 32 (32.0%) |
UA (mg/dl) | 8.0 (1.9–15.3)** | 5.7 (2.3–12.9) | E1 | 36 (72.0%) | 68 (68.0%) |
Hb (g/dl) | 12.2 ± 2.0* | 12.9 ± 1.8 | Segmental Glomerulosclerosis* | ||
Alb (g/dl) | 3.5 ± 0.8* | 3.9 ± 0.6 | S0 | 12 (24.0%) | 52 (52.0%) |
TC (mg/dl) | 207.7 (111.5–392.3)* | 184.6 (100.0–369.2) | S1 | 38 (76.0%) | 48 (48.0%) |
Proteinuria (g/day) | 2.9 (0.1–8.3)** | 0.8 (0–9.9) | Tubular atrophy/Interstitial fibrosis** | ||
Hypertension | 31 (62.0%)* | 47 (47.0%) | T0 | 16 (32.0%) | 86 (86.0%) |
Macro-hematuria | 2 (4.0%)* | 18 (18.0%) | T1 | 26 (52.0%) | 11 (11.0%) |
T2 | 8 (16.0%) | 3 (3.0%) |